In multiple myeloma and melanoma, MCL1 inhibitors like S63845 combined with HDAC inhibitors or redox modulators upregulate pro-apoptotic proteins like BIM and NOXA, resensitizing resistant cells [130,134]. This evidence concerns the gene MCL1 and plasma cell myeloma.